Last $5.43 USD
Change Today +0.03 / 0.56%
Volume 33.3K
As of 4:30 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

sorrento therapeutics inc (SRNE) Snapshot

Open
$5.37
Previous Close
$5.40
Day High
$5.49
Day Low
$5.37
52 Week High
03/21/14 - $16.40
52 Week Low
05/19/14 - $4.75
Market Cap
154.9M
Average Volume 10 Days
44.6K
EPS TTM
$-1.80
Shares Outstanding
28.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SORRENTO THERAPEUTICS INC (SRNE)

Related News

No related news articles were found.

sorrento therapeutics inc (SRNE) Related Businessweek News

No Related Businessweek News Found

sorrento therapeutics inc (SRNE) Details

Sorrento Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. Its lead product candidate, Cynviloq, is a micellar diblock copolymeric paclitaxel formulation currently approved and marketed in various countries, including South Korea, for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I or III trials for MBC, and Phase I or II trials in NSCLC, Ovarian, Bladder, and Pancreatic cancers. The company is also developing resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company is also developing antibody drug conjugates and recombinant intravenous immunoglobulin (rIVIG) for the treatment of certain auto-immune diseases, as well as immunodeficiencies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

50 Employees
Last Reported Date: 04/1/14
Founded in 2006

sorrento therapeutics inc (SRNE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $291.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

sorrento therapeutics inc (SRNE) Key Developments

Vuong Trieu Resigns as a Director of Sorrento Therapeutics, Inc

On August 20, 2014, Dr. Vuong Trieu resigned as a director of Sorrento Therapeutics, Inc.

Sorrento Therapeutics Announces Board Changes

Sorrento Therapeutics, Inc. announced the addition of industry veteran Douglas Ebersole to its Board of Directors. Mr. Ebersole has over 25 years of broad business experience in industry as well as from consulting in a number of advisory roles, including as a former partner in a Silicon Valley law firm. Currently, Mr. Ebersole is an independent consultant and has worked primarily with PDL BioPharma (PDL) since 2005. From 1992 to 2005, Mr. Ebersole served in various senior executive roles at PDL, including Senior Vice President -- Corporate Development and Legal. In addition, the company announced that Mr. Cam Gallagher has resigned from the Board of Sorrento following his appointment to the Board of Ark Animal Health, Inc.

Sorrento Therapeutics, Inc. Announces the Demise of Amar Singh, Chief Business Officer and Executive Vice President

Sorrento Therapeutics, Inc. announced the death of Amar Singh, chief business officer and executive vice president. Singh died suddenly and unexpectedly of apparent natural causes on July 30, 2014. Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where he served as SVP and chief business officer since December 2010.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRNE:US $5.43 USD +0.03

SRNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SRNE.
View Industry Companies
 

Industry Analysis

SRNE

Industry Average

Valuation SRNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 70.7x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORRENTO THERAPEUTICS INC, please visit www.sorrentotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.